$CBIS Cannabis Science CEO Prepares to Speak at Harvard Medical School This November 2016, Company Announces Clinical Research Studies to Begin Next Month As Well
Marketwired October 27, 2016
IRVINE, CA--(Marketwired - Oct 27, 2016) - Cannabis Science, Inc. ( OTC PINK : CBIS ), a U.S. company specializing in the development of cannabis-based medicines, is pleased to announce as its CEO Mr. Dabney prepares for his Harvard Medical School dissertation coming this November, the Company prepares to begin its Cannabis Science Clinical Research studies in November 2016.
These studies are expected to start as CEO Raymond Dabney readies to speak at Harvard Medical School. Mr. Dabney will speak at the Dana-Farber/Harvard Cancer Center (DF/HCC). This facility is one of the largest cancer research centers in the world, with more than 1,100 cancer researchers and over $600 million in cancer research funding. Mr. Dabney will discuss CBIS' drug development initiatives. The broader conversation will discuss the targeting of a variety of cancers, pain management, asthma, and autism spectrum disorder.
"We expect our Research Program and Laboratory to soon be complete and we will then be ready to start clinical studies," stated CEO Raymond Dabney. "Given the high number of applicants inquiring about the studies we regret that not all can be chosen to participate in these studies." The number of potential applicants was overwhelming and solidifies Cannabis Science as an emerging entity in the Cannabis Self Medicating arena.
Chief Medical Officer Dr. Allen Herman will oversee the clinical studies. Cannabis Science anticipates the results will aid CBIS in applying for an orphan drug designation. This approval could include an inhalation, metered-dose, cannabinoid pharmaceutical product to treat multiple conditions, in the marketplace in short order.
CBIS expects to file the applications shortly. Once the applications are submitted to the FDA, the designation and/or comments are expected within 90 days. These designations confer significant advantages including waiver of application filing fees, expedited approval, government grants, and reduced number of patients in clinical trials.
"The recent acquisitions and planned acquisitions of growing space and product development places Cannabis Science ahead of the competition to meet the ever growing demand of Cannabis Medicinal Products," stated Mr. Dabney. "We are taking the needed steps to meet this demand both nationally and globally, and will shortly roll-out the ecommerce section of our website to shareholders as well as California Residents ahead of the Prop 64 vote. This is an important step forward for Cannabis Science as well."
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
